49
Participants
Start Date
December 15, 2014
Primary Completion Date
October 25, 2016
Study Completion Date
August 20, 2018
Trastuzumab Emtansine
Trastuzumab emtansine will be administered intravenously (IV) at a dose of 3.6 mg/kg on Day 1 of every 21-day cycle until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the sponsor, whichever occurs first.
CHUV; Departement d'Oncologie, Lausanne
UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, Zurich
HELIOS Klinikum Emil von Behring Klinik f.Pneumologie Onkologie u.Infektiologie, Berlin
Istituto Europeo Di Oncologia, Milan
University of North Carolina at Chapel Hill, Chapel Hill
Hospital Ramon y Cajal; Servicio de Oncologia, Madrid
Hospital Universitario La Paz; Servicio de Oncologia, Madrid
Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville
Fachklinik für Lungenerkrankungen, Immenhausen
Kaiserswerther Diakonie Florence Nightingale-Krankenh. Tagesklinik f.Onkologie, Düsseldorf
Azienda Ospedaliera Univ Parma; Dept Oncologia Medica, Parma
Karmanos Cancer Institute, Detroit
Hospital Clinico Universitario Lozano Blesa; Servicio de Oncologia, Zaragoza
Rush University Medical Center, Chicago
Asklepios-Fachkliniken Muenchen-Gauting; Onkologie, Gauting
Seattle Cancer Care Alliance, Seattle
Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II, Halle
Medical University of Gdansk, Gdansk
Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock
Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii, Warsaw
Seoul National University Hospital, Seoul
Asan Medical Center - Oncology, Seoul
Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona
Hoffmann-La Roche
INDUSTRY